摘要
目的报告2例晚期肾癌新辅助治疗的成功经验,探讨靶向药物新辅助治疗的适应证、药物使用方法及手术时机。方法查阅2例患者的住院病史和门诊病历,分析原发肿瘤分期、影像学表现、多靶点药物治疗时间、毒副反应、病灶对药物的反应、手术时机、术中所见、病理报告和预后。结果患者接受靶向治疗36周,能耐受不良反应,影像学评价提示病灶稳定,停药2周后成功进行了肾根治性切除术加后腹膜淋巴结清扫术或转移病灶切除,术后恢复良好。结论新辅助治疗能够降低肿瘤分期,降低手术难度,增加晚期肾癌的根治性切除率,使原先无法手术的晚期肾癌患者接受手术治疗。靶向治疗后进行手术不增加围手术期死亡率和并发症发生风险,安全性较高。
Objective To report our experience of neoadjuvent therapy for advanced renal cell carcinoma,and discuss the indications and medication.Methods Medical records of these 2 patients were reviewed to find the duration of target therapy,toxicity,response of tumor,surgical approach,intraoperative findings,and pathology analysis.Results Two patients received 36-week of sunitinib and only suffered from mild to moderate adverse effects.After stopping sunitinib for 2 weeks,a transperitoneal radical nephrectomy and lymph node dissection and a transperitoneal radical nephrectomy and adrenalectomy were performed.Conclusions Neoadjuvant targeted therapy could allow surgical treatment in patients deemed to have unresectable disease,with no increased risk of surgical morbidity or wound complications.Further studies should focus on effects on recurrence-free survival after surgery.
出处
《现代泌尿生殖肿瘤杂志》
2011年第3期132-135,共4页
Journal of Contemporary Urologic and Reproductive Oncology
关键词
肾肿瘤
新辅助治疗
靶向治疗
Kidney neoplasms
Neoadjuvent therapy
Targeted therapy
